Terms: = Ovarian cancer AND BCL9, LGS, 607, ENSG00000116128, MGC131591 AND Treatment
17 results:
1. Morphological Changes of the ovarian Vein in Pelvic Venous Disorders.
Nykonenko A; Trailin A; Lazarashvili Z; Proczka RM; Havrylenko B; Nykonenko O
Eur J Vasc Endovasc Surg; 2024 Mar; 67(3):500-505. PubMed ID: 37952635
[TBL] [Abstract] [Full Text] [Related]
2. The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
Hendrikse CSE; Theelen PMM; van der Ploeg P; Westgeest HM; Boere IA; Thijs AMJ; Ottevanger PB; van de Stolpe A; Lambrechts S; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2023 Apr; 171():83-94. PubMed ID: 36841040
[TBL] [Abstract] [Full Text] [Related]
3. Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
Manning-Geist BL; Gordhandas SB; Giri DD; Iasonos A; Zhou Q; Girshman J; O'Cearbhaill RE; Zamarin D; Lichtman SM; Sabbatini PJ; Tew WP; Li K; McDonnell AS; Aviki EM; Chi DS; Aghajanian CA; Grisham RN
Gynecol Oncol; 2022 Jan; 164(1):12-17. PubMed ID: 34763937
[TBL] [Abstract] [Full Text] [Related]
4. Postoperative chemotherapy had no prognostic effect on early-staged young ovarian cancer with unilateral resection.
Zhang X; Wang S; Zhao S; Sun Y; Yang G
Cancer Med; 2018 Nov; 7(11):5488-5496. PubMed ID: 30306725
[TBL] [Abstract] [Full Text] [Related]
5. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of ovarian cancer Cells to Chemotherapy.
Zhang C; Zhang Z; Zhang S; Wang W; Hu P
Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
[TBL] [Abstract] [Full Text] [Related]
6. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
Spreafico A; Oza AM; Clarke BA; Mackay HJ; Shaw P; Butler M; Dhani NC; Lheureux S; Wilson MK; Welch S; Zhang T; Yu C; Stockley T; Siu LL; Kamel-Reid S; Bedard PL
Gynecol Oncol; 2017 Feb; 144(2):250-255. PubMed ID: 28062115
[TBL] [Abstract] [Full Text] [Related]
7. Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway.
Li B; Cai S; Zhao Y; He Q; Yu X; Cheng L; Zhang Y; Hu X; Ke M; Chen S; Zou M
Oncotarget; 2016 Dec; 7(49):81026-81048. PubMed ID: 27835587
[TBL] [Abstract] [Full Text] [Related]
8. Preoperative multiplication of neutrophil and monocyte counts as a prognostic factor in epithelial ovarian cancer.
Paik ES; Shim M; Choi HJ; Lee YY; Kim TJ; Choi CH; Lee JW; Kim BG; Bae DS
Cancer Biomark; 2016; 17(4):419-425. PubMed ID: 27802193
[TBL] [Abstract] [Full Text] [Related]
9. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous ovarian cancer.
Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
[TBL] [Abstract] [Full Text] [Related]
10. Committee opinion no. 607: Gynecologic concerns in children and adolescents with cancer.
Obstet Gynecol; 2014 Aug; 124(2 Pt 1):403-408. PubMed ID: 25050772
[TBL] [Abstract] [Full Text] [Related]
11. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Grisham RN; Iyer G; Sala E; Zhou Q; Iasonos A; DeLair D; Hyman DM; Aghajanian C
Int J Gynecol Cancer; 2014 Jul; 24(6):1010-4. PubMed ID: 24978709
[TBL] [Abstract] [Full Text] [Related]
12. Cost-effectiveness of early-initiated treatment for advanced-stage epithelial ovarian cancer patients: a modeling study.
Hoyer T; Bekkers R; Gooszen H; Massuger L; Rovers M; Grutters JP
Int J Gynecol Cancer; 2014 Jan; 24(1):75-84. PubMed ID: 24362714
[TBL] [Abstract] [Full Text] [Related]
13. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.
Bakrin N; Bereder JM; Decullier E; Classe JM; Msika S; Lorimier G; Abboud K; Meeus P; Ferron G; Quenet F; Marchal F; Gouy S; Morice P; Pomel C; Pocard M; Guyon F; Porcheron J; Glehen O;
Eur J Surg Oncol; 2013 Dec; 39(12):1435-43. PubMed ID: 24209430
[TBL] [Abstract] [Full Text] [Related]
14. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Grisham RN; Iyer G; Garg K; Delair D; Hyman DM; Zhou Q; Iasonos A; Berger MF; Dao F; Spriggs DR; Levine DA; Aghajanian C; Solit DB
Cancer; 2013 Feb; 119(3):548-554. PubMed ID: 22930283
[TBL] [Abstract] [Full Text] [Related]
15. Trabectedin for the treatment of relapsed ovarian cancer.
Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
[TBL] [Abstract] [Full Text] [Related]
16. A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery.
Ferguson SE; Malhotra T; Seshan VE; Levine DA; Sonoda Y; Chi DS; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2009 Jul; 114(1):111-6. PubMed ID: 19395071
[TBL] [Abstract] [Full Text] [Related]
17. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.
Bolis G; Favalli G; Danese S; Zanaboni F; Mangili G; Scarabelli C; Tateo S; Valsecchi MG; Scarfone G; Richiardi G; Frigerio L; Melpignano M; Villa A; Parazzini F
J Clin Oncol; 1997 May; 15(5):1938-44. PubMed ID: 9164205
[TBL] [Abstract] [Full Text] [Related]
